Details for New Drug Application (NDA): 007012

« Back to Dashboard

NDA 007012 describes VI-TWEL, which is a drug marketed by Bayer Hlthcare and is included in one NDA. Additional details are available on the VI-TWEL profile page.

The generic ingredient in VI-TWEL is cyanocobalamin. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.

Summary for 007012

Tradename:	VI-TWEL
Applicant:	Bayer Hlthcare
Ingredient:	cyanocobalamin
Patents:	0
Formulation / Manufacturing:	see details

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	1MG/ML
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.